Business

According to UCB, Nayzilam midazolam nasal spray will be available in the US as of December 2, 2019. UCB acquired the nasal spray from Proximagen in April 2018, and the FDA approved Nayzilam for the treatment of seizure clusters in epilepsy patients 12 years old and older in May 2019. The company said that Nayzilam is expected to cost $40 for a box containing two … [Read more...] about UCB announces US launch of Nayzilam midazolam nasal spray

DPI developer Iconovo has announced that the Japanese Patent Office has granted the company a patent covering its ICOres dry powder inhaler. According to Iconovo, Sweden and European patents related to ICOres have already been issued. In March 2019, Iconovo announced that CBC Corporation was taking over development responsibilities from Amneal Pharmaceuticals for … [Read more...] about Iconovo gets Japanese patent for ICOres DPI

Kind Consumer has announced the UK launch of its breath activated Voke 0.45mg nicotine inhaler, which will be available to consumers by direct online purchase at a price of £11.99. The Voke inhaler was approved by the MHRA for general sale for the relief or prevention of nicotine cravings and withdrawal symptoms in September 2014. In January 2017, British American … [Read more...] about Kind Consumer launches Voke nicotine inhaler in the UK

MannKind Corporation said that it has reached the second milestone in its development of Treprostinil Technosphere (“TreT”), a dry powder formulation of treprostinil for inhalation that the company is developing for the treatment of pulmonary arterial hypertension in partnership with United Therapeutics. In April 2019, MannKind announced that United Therapeutics had … [Read more...] about MannKind gets 2nd development milestone payment for dry powder treprostinil

Bryn Pharma, which recently announced that it would use Aptar's Bidose nasal device for delivery of its BRYN-NDS1C intranasal epinephrine, said that it has raised $17.5 million that it will use to prepare for US regulatory approval and commercialization of the nasal spray. BRYN-NDS1C has received Fast Track designation from the FDA, and the company plans to pursue … [Read more...] about Bryn Pharma raises $17.5 million to fund regulatory and commercial activities for its epinephrine nasal spray

TFF Pharmaceuticals, which is developing DPI formulations based on its thin film freezing (TFF) technology, has announced an initial public offering of 4,400,000 shares of common stock at $5.00 per share. Earlier this year TFF announced that it had raised $8.17 million through a Series A preferred stock offering. The company said that it expects to use the net … [Read more...] about TFF Pharmaceuticals announces IPO